Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective

Volume 20, Issue 2, February 2020, Page 151-161 .

Source: Expert Opinion on Biological Therapy - January 21, 2020 Category: Drugs & Pharmacology Authors: Patrick B. Allen Stefanos Bonovas Silvio Danese Laurent Peyrin-Biroulet Source Type: research